In a model based on HPTN 052 data, early ART initiation for the HIV-infected partner was very cost-effective over a lifetime in both South Africa and India.
In the HIV Prevention Trials Network (HPTN) 052 study, early antiretroviral therapy (ART) initiation (i.e., at CD4 counts 350–500 cells/mm3) for the HIV-infected partner in a serodiscordant couple was associated with a 96% decrease in HIV transmission compared with delayed ART initiation. Patients in the early-ART group also showed clear clinical benefits.
Now, using HPTN 052 data and a microsimulation model of HIV disease, progression, and treatment, investigators have projected the cost-effectiveness of early ART, compared with delayed ART, in serodiscordant couples in South Africa and India. These countries were chosen in part because they have high numbers of HIV-infected people but differ in economic conditions: South Africa is classifi…
Reviewing Authors
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresConsultant/Advisory BoardNIH Therapeutics and Prevention Data Safety Monitoring Board
Leadership Positions in Professional SocietiesAmerican Board of Internal Medicine Infectious Diseases Subspecialty Board (member), Infectious Diseases Society of America (Vice President)
DisclosuresConsultant/Advisory BoardNIH Therapeutics and Prevention Data Safety Monitoring Board
Leadership Positions in Professional SocietiesAmerican Board of Internal Medicine Infectious Diseases Subspecialty Board (member), Infectious Diseases Society of America (Vice President)